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Growth factors (GFs) supporting neuro-
nal survival and increasing their functional
activity are promising leads for the de-
velopment of disease-modifying treat-
ments for neurodegenerative disorders.
Clinical use of GFs requires careful plan-
ning with regard to dosing, delivery para-
digms and equipment, frequency of
administration, and the development of
patients’ stratification criteria.Yulia A. Sidorova1 and Mart Saarma1,*
Growth factors (GFs) hold considerable promise for disease modification in
neurodegenerative disorders because they can protect and restore degenerating
neurons and also enhance their functional activity. However, extensive efforts
applied to utilize their therapeutic potential in humans have achieved limited
success so far. Multiple clinical trials with GFs were performed in Parkinson’s
disease (PD) patients, in whom diagnostic symptoms of the disease are caused
by advanced degeneration of nigrostriatal dopamine neurons (DNs), but the re-
sults of these trials are controversial. This review discusses recent developments
in the field of therapeutic use of GFs, problems and obstacles related to this use,
suggests the ways to overcome these issues, and alternative approaches that
can be used to utilize the potential of GFs in PD management.Several alternatives to naturally occurring
GFs, such as mutant proteins or small
molecules targeting GF receptors, show
promise in animal models of Parkinson’s
disease (PD) and can progress to clinical
use with better outcomes.
Early diagnostics of PD and immediate
initiation of the treatment may signifi-
cantly improve clinical perspectives of
GF-based therapeutics.
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Neurodegeneration in Parkinson’s disease (PD; Box 1) starts from the axons of dopamine (DA)
neurons (DNs) in the putamen (Figure 1). When PD is diagnosed there is a 70–80% reduction
in the putaminal DA level, approximately 70% decrease in the density of DA axons, but only
30% reduction in the number of DN cell bodies in the substantia nigra pars compacta (SNpc)
[1,2]. Therefore, the remaining functional and dystrophic DNs represent an attractive target for
supportive and neurorestorative (see Glossary) therapeutic approaches, respectively, which
can be provided by growth factors (GFs) including neurotrophic factors (NTFs; Box 2).
GFs have been extensively tested in several preclinical PD models (PD models are described in
Box 3) and have shown considerable promise for disease modification. Some of them were
also trialed in PD patients, but the therapeutic success of such interventions was rather limited.
To critically evaluate the results of clinical trials conducted with GFs in PD patients it is important
to understand key differences in pharmacology and mode of action of GF treatments compared
with conventional small-molecule drugs. Importantly, GFs act in the organism via defined and
physiologically relevant molecular pathways in contrast to other agents which are potentially neu-
roprotective for DN (e.g., an antidiabetic drug exenatide) [3]. Moreover, GFs not only protect,
but also restore neurons, promote arborization and sprouting of their neurites, and enhance
the functional activity of neurons. These points justify further attempts to translate GFs into
drugs for PD treatment.
Special Aspects of GF Functioning Relevant for Their Clinical Translation
Biological activity of endogenous GFs in mammals is tightly controlled. GFs usually have a short
half-life in vivo. In the brain they are often released in a pulsatile manner and are rapidly bound to
their receptors in target tissues, internalized, recycled, or degraded. The short-term interaction of
GF with its receptor is sufficient for activation of intracellular signaling cascades necessary for
neuronal survival and functioning. Then the second messenger proteins in signaling cascades
activate transcription factors that trigger the expression of their target genes. While theTrends in Pharmacological Sciences, December 2020, Vol. 41, No. 12 https://doi.org/10.1016/j.tips.2020.09.010 909
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Glossary
1-Methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP): toxin that
is widely used to model PD as it
selectively destroys DA cells.
6-Hydroxydopamine (6-OHDA):
toxin is widely used to model PD
because it selectively destroys DA
cells. 6-OHDA is given with an
inhibitor of serotonin and noradrenalin
reuptake, as it is also toxic to
serotonergic and adrenergic neurons.
α-Synuclein: a protein involved in
neurotransmitter release that is expressed
in neuronal cells, especially in DNs at high
level. α-Synuclein tends to aggregate
especially when mutated and/or
overexpressed. Aggregated α-synuclein
is a major component of Lewy bodies
detected in the brains of the majority of
PD patients. According to general belief
α-synuclein aggregates cause the
neurodegeneration of DNs by interfering
with cellular processes. However, there
are data contrasting this view. Therefore,
the final conclusion of significance and
role of α-synuclein aggregation in PD is
yet to be made.
Dopamine transporter (DAT): a
transmembrane protein responsible for
reuptake of DA from the synaptic cleft
into cytosol. It is a widely used marker of
DNs in preclinical and clinical samples.
The DAT is generally considered to
express at a rather stable level through a
variety of conditions and treatments.
Neuroprotective: an ability of the test
substance to prevent thedeath of neurons
when given before/simultaneously with a
lesion.
Neurorestorative: properties that
manifest as an ability of the test substance
to structurally restore damaged cells by,
for example, stimulation of the neurite
outgrowth if given when the lesion is
already established.
Positronemission tomography (PET):
a method to estimate the level and
distribution of radioactively labeled
compound (tracer) in the living organism.
In PD patients 18F-DOPA is often used
as a tracer to evaluate activity of DATs
which to a certain extent correlates with
the severity of nigrostriatal DA system
degradation and motor impairment.
Tyrosine hydroxylase (TH): a key
enzyme of DA synthesis that is widely
used as a marker of DNs in preclinical
and clinical samples. The level of TH in
the cell can be upregulated and
downregulated upon certain treatments.
Box 1. Parkinson’s Disease: Prevalence, Symptoms, Pathophysiology
Parkinson’s disease (PD) affects 0.3% of the population, being more frequent in males and the elderly. The usual onset of
the disease occurs at an age of 65–70 years [73]. In the brains of PD patients dopamine (DA) neurons in substantia nigra
pars compacta (SNpc) degenerate and eventually die. This produces characteristic motor symptoms of the disease such
as tremor, rigidity, and slowness of movement, which form the basis for PD diagnosis. In addition to motor symptoms, PD
patients experience a number of non-motor symptoms including gastrointestinal tract disturbances, anosmia, sleep
disturbances, depression, sexual function deterioration, neuropsychiatric problems, postural hypotension, and cognitive
decline associated with the degeneration or dysfunction of other neuronal populations in the brain and other organs.
Non-motor symptoms may precede motor symptoms by several years or even decades [74,75].
Histopathological examination reveals the presence of Lewy bodies in the brains of PD patients. Lewy bodies are bulky
protein aggregates predominantly consisting of α-synuclein, but also more than 90 other proteins [76]. Prevailing concept
considers Lewy bodies as a cause of neurodegeneration by, for example, impairing axonal transport, although some
authors indicate their potential neuroprotective role mediated by sequestering cytotoxic oligomers of α-synuclein [76].
Importantly, there is an immense need in finding biomarkers for early and reliable diagnostics of PD. Currently the diagnosis
is based on manifestation of motor symptoms which appear when extensive degeneration in the nigrostriatal DA system
has already occurred, and even in the presence of motor symptoms it can be difficult to diagnose PD at the early stage of
the disease as some of themotor symptomsmay also appear in patients with other conditions. Introducing new diagnostic
methods based, for example, on the analysis of non-motor symptoms in combination with positron emission tomography
(PET) scanning using dopamine transporter (DAT) tracers can greatly improve the efficacy of neurorestorative treatments
allowing therapeutic intervention to be initiated when the lesion is mild and significant number of cells can be protected and
healed. Noteworthy, however, that non-motor symptoms are not specific for PD and patients with other diseases
often mention them as well. Finally, neurorestorative treatments should be initiated immediately after diagnosis as the dis-
ease is progressive and the remaining DNs gradually continue to degenerate, leaving only a small number of cells that can
be restored even in the 3–5 years after the diagnosis [5,6].
Trends in Pharmacological Sciencestransmission of a signal in a signaling cascade is a rapid process occurring within several minutes
after the application of a GF, transcriptional effects may result in significant rearrangements in cel-
lular processes and last for many days or even months after the inactivation of the GF (Figure 2A).
By contrast, prolonged activation of GF receptors can be detrimental for their biological effects
because of multiple negative feedbackmechanisms in signaling cascades aimed to restrict uncon-
trolled propagation and multiplication of a signal [4]. GFs often produce biphasic dose–response
curves in biological experiments [5] and in clinical trials [6], mediated by different mechanisms.
For instance, high concentrations of GFsmay inhibit the formation of functional oligomeric signaling
complexes because each monomer of the receptor is bound to a ligand molecule [7]. GFs at high
concentration can also trigger internalization pathways in the cell that elicit GF and receptor degra-
dation in short-term (Figure 2B) or suppression of receptor’s expression via various silencing
mechanisms in long-term experiments [8]. Both of these processes can be further augmented
by an insufficient amount of available chaperones necessary for efficient folding of newly synthe-
sized GF receptors. Excessive amount of GF can also trigger negative feedback mechanisms in
its downstream signaling cascades including dephosphorylation of activated receptors [9] or
second messengers by phosphatases and block the transmission of signal.
Elevated levels of GFs caused by continuous overexpression or infusion may also cause more
general negative effects in the DA system. In particular, glial cell line-derived neurotrophic factor
(GDNF) overexpression was shown to downregulate the level of tyrosine hydroxylase (TH),
the key enzyme of DA synthesis (DA synthesis and signaling are shown in Figure 1D) in rats
[10]. It can also cause aberrant sprouting and ectopic formation of synapses in the brain, thus
producing multiple adverse effects that can be dose dependent [11].
Importantly, GFs are often expressed in several isoforms and the activity or even their biological
effects can be different [12]. GFs are prone to degradation by intracellular and extracellular matrix
proteases and their half-life and stability can depend on post-translational modifications.910 Trends in Pharmacological Sciences, December 2020, Vol. 41, No. 12
Unified Parkinson’s Disease Rating
Scale (UPDRS): a scale used to
evaluate the severity of motor and non-
motor symptoms of PD. It encompasses
a list of questions requiring a subjective
evaluation of everyday life activities of the
patient and severity of symptoms and
the data collected during objective
motor examination performed by a
specialist. Efficacy and side effects of the
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Figure 1. Nigrostriatal Dopamine (DA) System in Healthy and Parkinson’s Brain (PD) and GF Actions in DA
Neurons (DNs). (A) Nigrostriatal pathway on the sagittal section of the brain. (B) Condition of the DA system in healthy
and PD brains, where DNs degenerate and eventually die (coronal sections). (C) Sites of actions of GFs in DNs. GFs do
not resurrect dead DNs (dark gray cells), but they protect healthy cells (brown), restore injured cells (red), increase the
functional activity of neurons (as shown by the high number of released mediator-containing vesicles, brown circles), and
(Figure legend continued at the bottom of the next page.
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Box 2. Neurotrophic Factors, Their Functions, and Signaling
Neurotrophic factors (NTFs) are small, secreted proteins mainly promoting the survival, protection, and restoration of
injured neurons. Most NTFs are synthesized as preproproteins and then are proteolytically cleaved to release the mature
form. Importantly, some proneurotrophic factors can also have biological effects different from those of mature NTFs. In
particular, while nerve growth factor (NGF) elicits trophic support to neurons, pro-NGF stimulates apoptosis [77].
Many proteins can influence different aspects of neuronal functioning, but only those that are able to promote the survival
of specific neuronal populations are considered NTFs. Currently, four families of NTFs have been discovered:
neurotrophins, neurokines, GDNF family ligands (GFLs), and the cerebral dopamine neurotrophic factor (CDNF)/mesence-
phalic astrocyte-derived neurotrophic factor (MANF) family.
Proteins from the first three families bind to specific cell surface receptors with kinase activity and activate intracellular
enzyme and kinase cascades such as PI3K/AKT, MAPK/ERK, Stat, Src, PLC-gamma, which are important for the survival
and functioning of neuronal cells (see Figure 2 in the main text) [78]. The receptors transmitting neuroprotective signals
from neurotrophins are tropomyosin receptor tyrosine kinases A, B, and C (Trk A–C). Neurotrophins and proneurotrophins
can also signal via the p75 neurotrophin receptor (p75NTR), a transmembrane glycoprotein and a member of the tumor ne-
crosis family (TNF) of receptors. Neurokine signaling occurs via a complex of ligand-selective low-affinity receptor and sig-
naling transmembrane gp130 receptors, which are constitutively associated with JAK (Janus kinase)-family tyrosine
kinases. GFLs signal mainly through the receptor tyrosine kinase rearranged in transfection (RET) and
glycosylphosphatidylinositol (GPI)-anchored coreceptor GFRα1–4 which provides ligand binding specificity. CDNF/MANF
proteins are localized in the endoplasmic reticulum and signal inside cells, but can be also secreted. Extracellularly deliv-
ered CDNF andMANF protect and restore DA neurons in animals models of PD [21,60,79,80], thus implying the existence
of signal-transducing extracellular receptors or internalization mechanisms for these proteins. The structure of MANF and
CDNF suggests that they can interact with lipids [81] which can in turnmediate intracellular uptake of these proteins as was
shown for lipid sulfatide instead of traditional transmembrane protein receptors [82]. In vitro and preclinical studies clearly
demonstrate neurorestorative properties of GFLs and CDNF/MANF in the nigrostriatal DA system, while neurotrophins
mainly have neuroprotective effects. Neurokines might have some effects in proliferation of DN precursor cells, which
seems to take place in mice, but occurs with very low frequency in humans (reviewed in [78]). Therefore, in this review,
we mainly focused on effects of GFLs and MANF/CDNF proteins in PD.
Trends in Pharmacological SciencesBiological activity and stability of recombinant GFs produced in bacterial systems which are used
in clinical trials can also differ from those of protein produced in eukaryotic cells [13,14].
The majority of clinical trials in PD patients were conducted using continuous infusion of high
doses of recombinant GFs or their constitutive overexpression from viral vectors in the brain
because GFs generally fail to penetrate through the blood–brain barrier (BBB) and often poorly
spread in tissues [15]. Therefore, they have to be either injected directly into the brain in the vicinity
of target neurons by means of complicated stereotactic surgery, modified to improve their BBB
penetration, or delivered using special techniques, such as nanoparticles. Problematic delivery,
features of biological responses of GFs, and their specific pharmacological properties limited
the success of clinical trials and resulted in premature conclusion on the lack of GF efficacy in PD.
GFs in Animal Models of PD: Effects and Problems in Clinical Translation
ManyGFs show the ability to protect DNs in animalmodels of PD (PDmodels are described in Box 3).
Several, in particular GDNF, neurturin (NRTN), mesencephalic astrocyte-derived neurotrophic factor
(MANF)/cerebral dopamine neurotrophic factor (CDNF), and platelet-derived growth factor (PDGF),
also showed neurorestorative effects in experimental animals. Detailed description of GF effects inmay induce axonal spouting. (D) Synapse diagram of a DN. DA is synthesized from amino acid tyrosine via two enzymatic
reactions catalyzed by tyrosine hydroxylase (TH; rate-limiting step) and DOPA decarboxylase (DDC) and packed into
secretory vesicles with the help of vesicular monoamine transporter 2 (VMAT2). Released DA in putamen binds to
postsynaptic DA receptors type 1 and 2 (D1–2) and interacts with presynaptic DA receptor D2x mediating negative
regulation of DA release. DA is reuptaken back into the presynaptic neuron terminal via the DA transporter (DAT) where i
can be either degraded by monoamine oxidase/catechol-O-methyltransferase (MAO/COMT) or repacked into secretory
vesicles by VMAT2. DOPAC/HVA (3,4-dihydroxyphenylacetic acid/homovanillic acid), or DA metabolites. Green arrows
represent the pathway which is stimulated by DA-releasing agents, such as amphetamine. Abbreviations: L-DOPA
dihydroxyphenylalanine; SNpc, substantia nigra pars compacta.
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Box 3. Modeling PD in Experimental Animals: Emerging Methods
Tomodel PD in experimental animals toxins, mechanical lesions, genetic manipulations, and α-synuclein preformed fibrils are
all used [83,84]. None of available models represents all PD features on a mechanism-related basis. Measurable parameters
in animal models of PD are motor deficits and non-motor symptoms. Also used is the status of the DA system by functional
(e.g., DA release or electric activity) and morphometric analysis of the nigrostriatal system (immunohistochemically using
antibodies against DN markers, e.g., TH, the key enzyme for DA synthesis), the dopamine transporter (DAT), the vesicular
monoamine transporter 2 (VMAT2; Figure 1D) or neuronal dyes such as Cresyl violet (Nissl staining).
The models of toxin-induced PD are well validated and widely used in drug discovery, but shed little light on disease mecha-
nisms. Multiple attempts have been made to develop better models of PD by knocking-in or knocking-out PD-related genes
in experimental animals. A vast majority of genetic models showmild and poorly reproducible DN degeneration althoughmotor
impairment and functional deficits are often reported. Perhaps the main limitation of most genetic PD models is related to the
fact that only 5–10% of patients have familial PD developed as result of inheritance of mutated genes. Therefore, such models
are representative only for minority of disease mechanisms [85]. Genetic models based on overexpression or muta-
tions in α-synuclein gene are clearly different in this regard as α-synuclein aggregates are found in the brains of the
majority of PD patients. Overexpression of α-synuclein from viral vectors was reported to induce the loss of DNs,
produce motor symptoms, and stimulate protein aggregation in nigrostriatal pathway [86], but these data turned out
to be difficult to reproduce and could have resulted from high levels of exogeneous protein in the brain [27,84]. Trans-
genic animals expressing wild-type or linked to human PD mutant α-synuclein generally exhibited only mild, if any,
degeneration of DNs [87]. Recently a new transgenic mice line characterized by the age-dependent loss of DNs
caused by expression of truncated 1–120 α-synuclein fragment has been established [88]. Also, initiation of Lewy
body-like pathology accompanied by the loss of TH-positive cells in SNpc was shown to be stimulated by preformed
α-synuclein fibrils injected into rodent brain [89,90]. A MitoPark model of PD was developed by selective deletion of
mitochondrial transcription factor Tfam in DNs and is characterized by slow progressive decline inmotor function and striatal
DA content, thus resembling the mitochondrial mechanism-based disease pathology asmitochondrial degeneration is asso-
ciated with PD development [91]. These three models may be very useful in the late stage of anti-PD drug discovery.
Trends in Pharmacological Sciencesanimalmodels is reviewed elsewhere [16–18]. Herewewill discuss several important issues related to
clinical translation of preclinical findings.
First, although GFs show profound effects in partial neurotoxin lesion models, their effects are
much less robust or even absent in animal models of severe PD [19–21]. At the same time, clinical
studies with GFs are mainly conducted in the late-stage PD patients who have lost the majority of
striatal DNs fibers and have much less nigral DNs compared with early stage patients, which com-
plicates the detection of potential therapeutic effects, especially in functional outcomes [1,22].
Another issue concerns the influence of protein aggregation on the expression of GF receptors.
Several publications reported that overexpression of α-synuclein from viral vectors in rodent
brain results in downregulation in expression of many genes, including GDNF receptor RET
(Figure 2B) and its upstream regulator, the transcription factor Nurr-1 [23,24]. Based mainly on
these data, one may conclude that limited efficacy of GDNF observed in clinical trials is related
to α-synuclein-induced decrease in RET expression. However, the expression of α-synuclein
mRNA in the brains of PD patients is not upregulated [25], instead it can even be downregulated
[26]. Evidence showing downregulation of GF receptors and Nurr-1 in the brains of PD patients
are absent [25]. Moreover, mild increase in α-synuclein mRNA level in rodent brains also fails to
downregulate the expression of NTF receptors [25]. It is also unclear whether the decrease in
RET and Nurr-1 expression [23,24] is caused specifically by α-synuclein aggregation or just
appears as a result of high level of heterologous protein in the brain in animal α-synuclein overex-
pression models of PD [27].
DNs in humans and experimental animals also have several important differences. At first, human
brain is much bigger compared with rodent brain. Every human midbrain DN forms 1–2 million
synapses, while rat neurons produce only 100 000–250 000 [28]. This results in a huge difference
in the energy and intracellular trafficking demand in these neurons. In addition, human neurons
should stay alive and function for much longer time compared with rodents’ because ofTrends in Pharmacological Sciences, December 2020, Vol. 41, No. 12 913
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Trends in Pharmacological Sciencesinterspecies difference in the life span. Although the exact reasons for DN vulnerability and death
in PD are unknown, some studies suggest that their normal activity can be a risk factor because of
neurotoxic effects of DA [29] and/or dysfunction of calcium homeostasis [30]. Thus, rodent DNs
may exhibit different susceptibility to degenerative and regenerative stimuli compared with human
cells. Recent achievements in stem cell research may finally result in the development of animal
models with grafted human stem cell-derived DNs for drug testing, thus improving translation
perspectives of novel PD therapeutics.
GFs can also have important applications in stemcell-based therapies that now are being trialed in PD
patients (reviewed in [31]), as they promote survival and functional integration of the grafted cells [32].
GFs in Clinical Trials in PD Patients
Based on promising results in moderate neurotoxin-lesioned animal models of PD, four GFs
(PDGF, GDNF, NRTN, and CDNF) were chosen for clinical trials in PD patients. Intracranially de-
livered recombinant PDGF protein has been, and CDNF protein is being, tested in small-scale
Phase I/II clinical trials in PD patients with the main goal to evaluate the safety and tolerability of
the treatment as well as signs of efficacy. PDGF was well tolerated and its main adverse effects
were associated with implantation of the delivery device. It improved the dopamine transporter
(DAT) function in positron emission tomography (PET) scans at least in some patients. All pa-
tients showed improvement in motor function evaluated using theUnified Parkinson’sDisease
Rating Scale (UPDRS) by an average of 4.5 points compared with baseline, but no differences
between placebo and PDGF-treated groups were reported [33]. In animal models of PD, PDGF
was shown to stimulate neurogenesis in the subventricular zone and thus improve the condition
of the nigrostriatal DA system [34]. While reported in some model organisms, it is unclear if
neurogenesis occurs in adult human midbrain [35]; therefore, the lack of PDGF efficacy in PD pa-
tients may be related to mechanistic difference between species.
A 1-year CDNF Phase I/II clinical trial was completed in August 2020; however, the main results
are yet to be reported. The data from the first 6-month evaluation show that CDNF is safe for pa-
tients and improves DAT function in PET imaging in some patients, thus supporting the disease-
modifying potential of this protein in PD (Herantis Pharma Plc and University of Helsinki, press
releasesi,ii). According to the newsletter published by Herantis Pharma Plc, the treatment was
found to be safe also after 12 months of administration and showed signs of efficacy such as
motor and DAT function improvements at least in some patientsiii.
GDNF family ligands (GFLs) have been studied in PD patients much more extensively. In the first
Phase II clinical trial, intraventricularly delivered GDNF did not improve motor performance ofFigure 2. Growth Factor (GF) Signaling. (A) Simplified scheme of GF signaling in the cells, showing, as an example
activation of mitogen-activated protein kinase (MAPK)/protein kinase B (AKT) pathways via receptor tyrosine kinase (RTK
and signal transducer and activator of transcription (STAT) pathway via the neurokine receptor (NKR). GFs bind to cel
surface receptors and via transmembrane receptor cytoplasmic domains activate intracellular second messengers. This
leads to stimulation of gene expression and results in cellular events, such as survival and neurite outgrowth. RTKs mediate
both rapid events via changes in phosphorylation status of multiple proteins and long-lasting effects via activation o
transcriptional mechanisms. NKRs mainly activate transcription of various proteins in the cells. (B) Glial cell line-derived
neurotrophic factor (GDNF) and neurturin (NRTN) signaling. Homodimeric GDNF and NRTN bind to
glycosylphosphatidylinositol (GPI)-anchored coreceptors GFRα1/2 and activate a transmembrane receptor tyrosine kinase
(RET). The signaling complex is internalized and either degraded or recycled. Intracellular signaling cascades are activated by
both cell surface and endosomal receptor/ligand complex. In the presence of GFRα1 receptor GDNF can also signal via
neural cell adhesion molecule (NCAM) or can directly bind to and signal via Syndecan-3. Abbreviations: ERK, extracellula
signal-regulated kinase; GFRα1/2, GDNF family receptor alpha-1/2; GRB2, growth factor receptor-bound protein 2; MEK
mitogen-activated protein kinase kinase; mTORC1, mammalian target of rapamycin complex 1; PDK1, 3-phosphoinositide-
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Trends in Pharmacological Sciencespatients as it failed to reach target neurons due to its inability to cross cell barriers. Serious treatment-
related adverse effects such as nausea, anorexia, weight loss, paresthesia, and pain were reported
[36]. Better understanding of GFLs biodistribution features resulted in two small-scale Phase I open-
label trials in which intraputaminally delivered GDNF decreased UPDRS values and increased fluo-
rine-18-dihydroxyphenylalanine (18F-DOPA) uptake on PET scans by 19% in the absence of signif-
icant adverse effects [37,38]. The effect of the treatment persisted for several months after the
withdrawal of treatment [39]. A subsequent Phase II randomized placebo-controlled clinical trial de-
signed to replicate these findings failed to reach its primary endpoints [40]. Although the treatment
was rather well tolerated, some adverse effects (mainly paraesthesia and headache) and the devel-
opment of GDNF-neutralizing antibodies in some patients were reported. The design of this clinical
trial, GDNF dose, GDNF delivery system, and administration regimen have received significant crit-
icism [41–43]. Formation of anti-GDNF antibodies (which remained largely unexplained and can only
be associated with peripheral leakage of GDNF) together with cerebellar toxicity of high doses of
GDNF reported in monkeys [44] transformed the delivery protocol in GDNF clinical trials to a more
physiological pulsatile one. Intermittent convection-enhanced administration of GDNF produced nei-
ther toxic effects in non-human primates [45] nor anti-GDNF antibodies in PD patients [46]. The re-
sults of a recent Phase II clinical trial indicated that intermittent intraputaminal administration of GDNF
is well tolerated. Although this study also failed to reach its primary endpoints, all patients in the
GDNF-treated group had significantly higher 18F-DOPA uptake on PET scans; in post hoc analysis
43% of them showed an improvement in UPDRS by at least 10 points (compared with 0% in the
placebo-treated group) and, importantly, 95%of patients receivingGDNF for 80weeks had clinically
significant improvements in at least one outcomemeasure [46,47]. Similarly, adeno-associated virus
2 vector (AAV2)-encoded GDNF produced an increase in 18F-DOPA uptake in patients and was
shown to be safe and well tolerated [48].
Another GFL, NRTN, was administered to PD patients with the help of AAV2 vector (AAV2-NRTN,
and CERE-120). Similar to GDNF, intracranially delivered AAV2-NRTN was safe for patients in
both short- and long-term studies [49–51]. At first, AAV2-NRTN was infused only into putamen,
but postmortem analysis of the brains of several patients revealed the presence of NRTN protein
only in a few DN bodies in SNpc, suggestive of impaired retrograde transport [52,53]. Therefore,
in the latest clinical trial CERE-120 was infused into both striatum and SNpc. Neither of the clinical
trials with AAV2-NRTN met primary endpoints, meaning that the patients showed no improve-
ments in functional outcome measures.
Important to note here is that the assessment of outcomes of clinical trials in PD patients is com-
plicated by placebo-related responses which are reported in the majority of these trials. Analysis
of the data of 858 PD patients assigned to placebo groups in 11 clinical trials revealed that the
overall placebo response rate (defined as ≥50% improvement in UPDRS score or a decrease
by ≥2 points on 2 or more UPDRS items) was in average equal to 16% [54]. In another small
study (n = 12) the magnitude of placebo-induced response in acute settings showed up to
28% reduction in UPDRS score [55].
GDNF [56] or CERE-120 [57] increased the density of TH-positive fibers in putamina of PD pa-
tients. In patients treated with CERE-120, TH expression comparable in intensity with that seen
in the brains of healthy age-matched controls was detected in areas also positive for NRTN
[53,57]. In addition, the levels of pERK (phosphorylated extracellular signal-regulated kinase)
and pS6, second messengers in mitogen-activated protein kinase (MAPK) and protein kinase
B (AKT) signaling cascades (Figure 2A) triggered by NRTN via RET, were elevated in SNpc of pa-
tients treated with CERE-120 delivered into both putamen and SNpc [57]. These data show that
GFLs are also able to produce trophic effects in human DNs.916 Trends in Pharmacological Sciences, December 2020, Vol. 41, No. 12
Trends in Pharmacological SciencesHowever, overall increase in the density of TH-positive fibers in putamina of CERE-120-treated
patients was rather modest and highly variable. The portion of putamen with increased TH
staining did not exceed 30%; the density of remaining TH-positive fibers was highly variable
and constituted only 3.9–21.6% of that in age-matched controls [57].
GFLs have high affinity for extracellular matrix and cell surface heparin sulfates containing proteins
(Figure 2B) and, therefore, they poorly diffuse in tissues [15]. Thus, only a portion of putamen is
covered by infused or viral vector-encoded GFL. The portion of putamen covered by GDNF in
the clinical trial conducted by Lang et al. [40] was estimated to be in the range of 2–9% [43]; in
Whone et al.’s [46,47] clinical trial, up to 57%; and in Heiss et al.’s trial [48], on average about
26%; in the AAV2-NRTN trial, NRTN expression was detected in postmortem brain samples in
3.75–22% of putamen [53,57]. These estimates were made by immunochemistry [43,57] or
based on the distribution of the contrasting agent gadolinium [46–48]. It is possible that neither
of these methods fully reflects the distribution of GFs in effective concentrations in the brain.
The effective concentrations of GFs may be lower than that detected by antibody or an antibody
can detect very low concentrations of GFs insufficient to produce a biological response. In this
regard, the analysis of GF-induced signaling in DNs can be a better method and it is possible
that the putamen coverage by GFLs in patients is overestimated.
One of the major limitations of clinical trials with GFs in PD is the need for surgical delivery of
the drug directly into the brain. This leads to the selection of patients with moderate to
advanced PD in clinical trials because of ethical constraints. Indeed, all clinical trials with
GDNF and NRTN were conducted in patients with PD duration of at least 10 years in average.
However, post hoc analysis of AAV2-NRTN clinical trial data revealed that the most responsive
cohort is patients with a duration of PD below 5 years [58]. This can be explained by the pro-
gressive nature of PD and low number of DNs and their fibers which GFs are expected to sup-
port and restore in late-stage patients [1]. It was shown that only a few TH- and DAT-positive
fibers remained in the putamina of patients 5 years after PD diagnosis and overall reduction in
optical density of TH-positive fibers at this time point reached up to 90%, remaining at the
same level for a decade or even two [22]. Even in early stage PD patients (3 years
postdiagnosis) the degree of DA fibers loss varied from moderate to marked [22]. Thus, the
variability produced by differences in GFL diffusion, extent of trophic effects, stage of the dis-
ease, and the rate of disease progression make it difficult to see statistically significant motor
improvement in patients when all of them are pooled together. The development of better
spreading variants of GFs and patient stratification in clinical trials are necessary future
steps in clinical translation of GFs in PD.
Potential Alternatives to Native GDNF and NRTN in Translational Research
Obstacles related to the delivery and tissue distribution of wild-type GFs have stimulated research
focused on finding alternative methods (summarized in Table 1, Key Table) to utilize their clinical
potential in PD.ModifiedGFs have been developed and tested in animal models of PD.Mutagenesis
in heparin-binding domains of GDNF andNRTNproduced several variants with greatly improved dif-
fusion in brain parenchyma [14,59]. GDNF mutants had reduced functional activity [59], but NRTN
variants exhibited significantly enhanced activity in vivo [14].
MANF and CDNF proteins diffuse in the striatum better compared with GFLs [21,60]. Addi-
tionally, structurally they include two biologically active domains and can, therefore, be split
to further reduce the size of protein and improve their biodistribution [61]. Full-length MANF
and CDNF, however, still have to be delivered intracranially, as they fail to cross through the
BBB; thus their clinical use can be limited by ethical restrictions in patient selection whichTrends in Pharmacological Sciences, December 2020, Vol. 41, No. 12 917
Key Table
Table 1. Problems Related to Clinical Use of GFs and the Ways to
Resolve Them
Problem Possible solution(s)
Requirement for surgical delivery due to inability to
cross BBB
Development of fusion proteins, peptides, or small
molecules penetrating through BBB
Poor spreading in target tissues Using convection-enhanced delivery system, alternative
GFs with better tissue distribution, such as CDNF, mutant
GFs, peptides, or small molecules
Biphasic dose–response curves Intermittent delivery of close to physiological doses of GFs,
regulated overexpression from viral vectors, administration of
short-lived small molecules or peptides at regular intervals
(e.g., once in 3 days)
Variability of response to the treatment in the
subpopulations of patients
Patient stratification criteria in clinical trials should be
developed. Early stage patients seem to respond to the
treatment with GFs better. Rate of disease progress may
also play a role.
Treatment-associated adverse effects Intermittently delivered GFs at close to physiological
doses seem to be well tolerated by patients. Continuous
infusion or constitutive high-level overexpression may
have detrimental effects and have to be avoided.
Development of antibodies to GFs Development of anti-GF antibodies is unlikely if GFs are
delivered into the brain. The integrity of containers and
tubing implanted in patients have to be closely monitored.
Small molecules and peptides can be used as
non-immunogenic alternatives.
Surgery-related complications in clinical trials BBB-penetrating forms of mutant GFs, small molecules,
and peptides can be used.
Variations in biological activity between batches of
recombinant proteins
Biological activity rather than quantity of GF should be
assessed for each batch. Production of GF in mammalian
cells may result in more physiological post-translationally
modified (e.g., glycosylated) forms and improve biological
activity and stability.
Detrimental effects of constitutive overexpression or
injection of high doses of recombinant GF with regard
to their biological activity (receptor downregulation,
negative feedback mechanism activation, gene
expression downregulation, etc.)
Intermittent delivery of proteins and regulated expression
of viral vectors with aim to deliver close to physiological
doses of GFs may represent a way to overcome these
negative effects and progress with clinical trials in PD
patients. The safety of intermittent delivery paradigm was
shown in the latest trials with GDNF protein [46,47]
Trends in Pharmacological Sciencesfavor the choice of late-stage patients due to the invasiveness of the treatment and brain
surgery-related complications.
To eliminate the need for intracranial delivery, GDNF was fused with peptides binding to
transport proteins in BBB, such as HIV-1-Tat-derived cell-penetrated peptide (Tat-GDNF)
[62] and heavy chain of monoclonal antibody against transferrin receptor (TfRMAb-GDNF)
[63]. Intraperitoneally injected Tat-GDNF crossed the BBB and reached nigrostriatal DNs,
but showed no neuroprotective activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP)-treated mice, perhaps because of either insufficient concentration in the brain or
the lack of functional activity (which was not assessed in the study) [62]. Functionally active
TfRMAb-GDNF penetrated BBB [although the brain uptake was rather low (about 3% of
intravenously injected dose)] [63], was well tolerated [64], improved motor function, and
increased TH activity in striata of mice in the 6-hydroxydopamine (6-OHDA) model of
PD [65]. Chronic administration of TfRMAb-GDNF led to the development of antibodies918 Trends in Pharmacological Sciences, December 2020, Vol. 41, No. 12
Outstanding Questions
What are the best doses for GFs in
clinical trials in PD patients?
How can we limit the detrimental effects
of high doses of GFs in regard to
downregulation of gene expression,
reduction in the number of receptors on
cell surface, and activation of negative
feedback mechanisms in the cells?
How can we select the most
responsive PD patients for GF-based
treatments?
What is the best way to target GF
receptors in PD patients?
How can we improve tissue spreading
of GFs?
Is there a possibility to avoid the need
for brain surgery which is currently
used to deliver GFs into the brains of
PD patients?
Can we utilize the potential of GFs to
target non-motor symptoms in PD
patients?
Is it possible to target both motor and
non-motor symptoms of PD with one
drug?
Trends in Pharmacological Sciencesagainst TfRMAb, but not GDNF itself, which seemed to have no influence on pharmacoki-
netics of the fusion protein [64].
In rodents intranasal delivery of either naked or nanoparticle-protected plasmids encoding GDNF
was shown to protect DNs from 6-OHDA-induced death [66]. Whether this approach can also
stimulate neurorestoration and if it is applicable to humans is yet to be studied, as previous
attempts to use gene therapy in PD showed significant differences between model organisms
and patients in terms of, for example, transport of virally encoded protein from striatum to SNpc [52].
Another option is to target the receptors of GFs with peptides or small molecules able to penetrate
through BBB and spread in the body targeting motor and non-motor symptoms of PD via trophic
support to both DN and, for example, olfactory, basal forebrain, enteric, and other neurons.
GDNF-derived peptides targeting one of its receptors neural cell adhesion molecule (NCAM) sup-
ported the survival of cerebellar granule cells and promoted neurite outgrowth from both these and
DNs in vitro. However, they failed to support the survival of DNs in culture [67] which indicates that
NCAM is unlikely to play a significant role in this process. A peptide containing 11 sequential amino
acid residues from the proregion of GDNF (DNSP-11) increased the survival of cultured DNs.
DNSP-11 delivered into SNpc was internalized by DNs in healthy rats, reduced motor symptoms,
and increased the concentration of striatal DA in the rat 6-OHDA PD model with a marked lesion.
However, it signaled via different receptors compared with GDNF as it failed to bind GDNF family
receptor alpha-1 (GFRα1), retained activity in the presence of the kinase inhibitor staurosporine,
and in a pull-down assay interacted mainly with metabolic proteins which are not downstream
targets of the GDNF/GFRα1/RET axis [20].
To the best of our knowledge no biologically active peptides selectively targeting the main GFL
receptor RET have been described so far and our own attempts to design such molecules
have remained unsuccessful (Y.A. Sidorova et al., unpublished). We, nevertheless, developed
three structurally unrelated chemical scaffolds selectively targeting and activating RET [68–71].
We showed that compounds belonging to one of these scaffolds penetrate through the BBB,
support the survival of cultured DNs, protect them from MPTP- and 6-OHDA-induced cell
death, stimulate release of DA in mouse brain, and alleviate motor symptoms in the 6-OHDA
model of PD [68,72]. The second and third scaffolds are yet to be tested in the DA system. Further
optimization of these chemicals to improve their biological activity and druglike properties may
eventually convert them into orally administrated disease-modifying treatments against PD.
Concluding Remarks
Although attempts to use GFs in clinical settings have a long history, these proteins are yet to
demonstrate their full potential in PD patients. GF-based therapeutics are different from conven-
tional small-molecule drugs in many aspects and their use requires careful design of clinical trials
(see Outstanding Questions). Patient stratification, dose, and the delivery method should be
meticulously considered in the future studies of GFs in PD patients. Nonlinear dose–response
and pulsatile nature of GF release under physiological conditions favors intermittent administration
of moderate doses of the proteins or the use of regulated gene therapy vectors in clinical trials in
order to limit upregulation of various negative feedback mechanisms. Patient recruitment strategy
should favor the selection of early stage PD patients to ensure the participation of people with
sufficient numbers of remaining DNs in SNpc. Clinically favorable alternatives such as mutated
GFs with improved tissue distributions, small molecules targeting GF receptors, and BBB-
penetrating peptides should be seriously considered for further development of disease-
modifying treatments against PD. Using alternatives to GF with improved tissue-penetrating ability,Trends in Pharmacological Sciences, December 2020, Vol. 41, No. 12 919
Trends in Pharmacological Sciencesfor example, small molecules, can also provide a way to target not only motor, but also non-motor
symptoms of PD. In summary, clinical trials with GF-based therapeutics in PD patients should be
continued in the future to find a cure for millions of affected people, but their design should be con-
siderably improved.
Acknowledgments
The authors thank Professor Barry Hoffer, Professor Anders Bjorklund, Professor Jaanus Harro, Dr Satu Kuure, Dr Mikko
Airavaara, and Dr Päivi Pulkkila for critical comments on the manuscript. Y.A.S. is supported by a grant from the Academy of
Finland (No. N1325555) and M.S. by a grant from the S. Juselius Foundation. The figures were created with BioRender.com.
The manuscript was proof-read by Professor Barry Hoffer.
Disclaimer Statement
M.S. is a co-founder and shareholder of Herantis Pharma, a company which conducts clinical development of CDNF. Y.A.S.







1. Cheng, H.C. et al. (2010) Clinical progression in Parkinson dis-
ease and the neurobiology of axons. Ann. Neurol. 67, 715–725
2. Burke, R.E. and Malley, K.O. (2013) Axon degeneration in
Parkinson’s disease. Exp. Neurol. 246, 72–83
3. Aviles-Olmos, I. et al. (2013) Exenatide and the treatment of pa-
tients with Parkinson’s disease. J. Clin. Invest. 123, 2730–2736
4. Lake, D. et al. (2016) Negative feedback regulation of the ERK1/2
MAPK pathway. Cell. Mol. Life Sci. 73, 4397–4413
5. Hou, J.G. et al. (1996) Glial cell line-derived neurotrophic factor
exerts neurotrophic effects on dopaminergic neurons in vitro
and promotes their survival and regrowth after damage by
1-methyl-4-phenylpyridinium. J. Neurochem. 66, 74–82
6. Backonja, M. et al. (2017) Safety and efficacy of neublastin in
painful lumbosacral radiculopathy. Pain 158, 1802–1812
7. Schlee, S. et al. (2006) Quantitative analysis of the activation
mechanism of the multicomponent growth-factor receptor Ret.
Nat. Chem. Biol. 2, 636–644
8. Sommerfeld, M.T. et al. (2000) Down-regulation of the
neurotrophin receptor TrkB following ligand binding. J. Biol.
Chem. 275, 8982–8990
9. Yadav, L. et al. (2020) PTPRA phosphatase regulates GDNF-
dependent RET signaling and inhibits the RET mutant MEN2A
oncogenic potential. iScience 23, 100871
10. Georgievska, B. et al. (2004) Overexpression of glial cell line-derived
neurotrophic factor using a lentiviral vector induces time- and dose-
dependent downregulation of tyrosine hydroxylase in the intact
nigrostriatal dopamine system. J. Neurosci. 24, 6437–6445
11. Georgievska, B. et al. (2002) Aberrant sprouting and downregu-
lation of tyrosine hydroxylase in lesioned nigrostriatal dopamine
neurons induced by long-lasting overexpression of glial cell line
derived neurotrophic factor in the striatum by lentiviral gene
transfer. Exp. Neurol. 177, 461–474
12. Lonka-Nevalaita, L. et al. (2010) Characterization of the intracellular
localization, processing, and secretion of two glial cell line-derived
neurotrophic factor splice isoforms. J. Neurosci. 30, 11403–11413
13. Saarenpää, T. et al. (2017) Zebrafish GDNF and its co-receptor
GFRα1 activate the human RET receptor and promote the sur-
vival of dopaminergic neurons in vitro. PLoS One 12, e0176166
14. Runeberg-Roos, P. et al. (2016) Developing therapeutically more
efficient neurturin variants for treatment of Parkinson’s disease.
Neurobiol. Dis. 96, 335–345
15. Bespalov, M.M. et al. (2011) Heparan sulfate proteoglycan
syndecan-3 is a novel receptor for GDNF, neurturin, and
artemin. J. Cell Biol. 192, 153–169
16. Paul, G. and Sullivan, A.M. (2019) Trophic factors for Parkinson’s
disease: where are we and where do we go from here? Eur.
J. Neurosci. 49, 440–452
17. Torres, N. et al. (2017) Neuroprotective surgical strategies in
Parkinson’s disease: role of preclinical data. Int. J. Mol. Sci. 18, 2190
18. Padel, T. et al. (2016) Platelet-derived growth factor-BB has
neurorestorative effects and modulates the pericyte response
in a partial 6-hydroxydopamine lesion mouse model of
Parkinson’s disease. Neurobiol. Dis. 94, 95–105
19. Hoffer, B.J. et al. (1994) Glial cell line-derived neurotrophic factor
reverses toxin-induced injury to midbrain dopaminergic neurons
in vivo. Neurosci. Lett. 182, 107–111
20. Bradley, L.H. et al. (2010) Dopamine neuron stimulating actions
of a GDNF propeptide. PLoS One 5, e9752
21. Voutilainen, M.H. et al. (2011) Chronic infusion of CDNF prevents
6-OHDA-induced deficits in a rat model of Parkinson’s disease.
Exp. Neurol. 228, 99–108
22. Kordower, J.H. et al. (2013) Disease duration and the integrity of the
nigrostriatal system in Parkinson’s disease. Brain 136, 2419–2431
23. Lo Bianco, C. et al. (2004) Lentiviral nigral delivery of GDNF does
not prevent neurodegeneration in a genetic rat model of
Parkinson’s disease. Neurobiol. Dis. 17, 283–289
24. Decressac, M. et al. (2012) α-Synuclein-induced down-
regulation of Nurr1 disrupts GDNF signaling in nigral dopamine
neurons. Sci. Transl. Med. 4, 163ra156
25. Su, X. et al. (2017) Alpha-synuclein mRNA is not increased in
sporadic PD and alpha-synuclein accumulation does not block
GDNF signaling in Parkinson’s disease and disease models.
Mol. Ther. 25, 2231–2235
26. Kingsbury, A.E. et al. (2004) Alteration in α-synuclein mRNA
expression in Parkinson’s disease. Mov. Disord. 19, 162–170
27. Albert, K. et al. (2017) AAV vector-mediated gene delivery to
substantia nigra dopamine neurons: implications for gene
therapy and disease models. Genes (Basel) 8, 63
28. Beeler, J.A. and Kisbye Dreyer, J. (2019) Synchronicity: the role
of midbrain dopamine in whole-brain coordination. eNeuro 6
ENEURO.0345-18.2019
29. Bozzi, Y. and Borrelli, E. (2006) Dopamine in neurotoxicity and
neuroprotection: what do D2 receptors have to do with it?
Trends Neurosci. 29, 167–174
30. Michel, P.P. et al. (2016) Understanding dopaminergic cell death
pathways in Parkinson disease. Neuron 90, 675–691
31. Parmar, M. et al. (2020) The future of stem cell therapies for
Parkinson disease. Nat. Rev. Neurosci. 21, 103–115920 Trends in Pharmacological Sciences, December 2020, Vol. 41, No. 12
Trends in Pharmacological Sciences32. Gantner, C.W. et al. (2020) Viral delivery of GDNF promotes
functional integration of human stem cell grafts in Parkinson’s
disease. Cell Stem Cell 26, 511–526.e5
33. Paul, G. et al. (2015) Safety and tolerability of intracerebroventricular
PDGF-BB in Parkinson’s disease patients. J. Clin. Invest. 125,
1339–1346
34. Zachrisson, O. et al. (2011) Restorative effects of platelet derived
growth factor-BB in rodent models of Parkinson’s disease.
J. Parkinsons Dis. 1, 49–63
35. Sorrells, S.F. et al. (2018) Human hippocampal neurogenesis
drops sharply in children to undetectable levels in adults. Nature
555, 377–381
36. Nutt, J.G. et al. (2003) Randomized, double-blind trial of glial cell
line-derived neurotrophic factor (GDNF) in PD. Neurology 60,
69–73
37. Gill, S.S. et al. (2003) Direct brain infusion of glial cell line–
derived neurotrophic factor in Parkinson disease. Nat. Med.
9, 589–595
38. Slevin, J.T. et al. (2005) Improvement of bilateral motor functions in
patients with Parkinson disease through the unilateral intraputaminal
infusion of glial cell line-derived neurotrophic factor. J. Neurosurg.
102, 216–222
39. Slevin, J.T. et al. (2007) Unilateral intraputamenal glial cell line–
derived neurotrophic factor in patients with Parkinson disease:
response to 1 year of treatment and 1 year of withdrawal.
J. Neurosurg. 106, 614–620
40. Lang, A.E. et al. (2006) Randomized controlled trial of
intraputamenal glial cell line-derived neurotrophic factor infusion
in Parkinson disease. Ann. Neurol. 59, 459–466
41. Penn, R.D. et al. (2006) GDNF in treatment of Parkinson’s disease:
response to editorial. Lancet Neurol. 5, 202–203
42. Hutchinson, M. et al. (2007) GDNF in Parkinson disease: an
object lesson in the tyranny of type II. J. Neurosci. Methods
163, 190–192
43. Salvatore, M.F. et al. (2006) Point source concentration of GDNF
may explain failure of phase II clinical trial. Exp. Neurol. 202,
497–505
44. Hovland, D.N. et al. (2007) Reprint: Six-month continuous
intraputamenal infusion toxicity study of recombinant methionyl
human glial cell line-derived neurotrophic factor (r-metHuGDNF)
in rhesus monkeys. Toxicol. Pathol. 35, 1013–1029
45. Luz, M. et al. (2018) Intermittent convection-enhanced delivery of
GDNF into rhesus monkey putamen: absence of local or
cerebellar toxicity. Arch. Toxicol. 92, 2353–2367
46. Whone, A.L. et al. (2019) Extended treatment with glial cell line-
derived neurotrophic factor in Parkinson’s disease. J. Parkinsons
Dis. 9, 301–313
47. Whone, A. et al. (2019) Randomized trial of intermittent
intraputamenal glial cell line-derived neurotrophic factor in
Parkinson’s disease. Brain 142, 512–525
48. Heiss, J.D. et al. (2019) Trial of magnetic resonance–guided
putaminal gene therapy for advanced Parkinson’s disease.
Mov. Disord. 2, 1–5
49. Marks, W.J. et al. (2016) Long-term safety of patients with
Parkinson’s disease receiving rAAV2-Neurturin (CERE-120)
gene transfer. Hum. Gene Ther. 27, 522–527
50. Marks, W.J. et al. (2008) Safety and tolerability of intraputaminal
delivery of CERE-120 (adeno-associated virus serotype 2-neurturin)
to patients with idiopathic Parkinson’s disease: an open-label,
phase I trial. Lancet Neurol. 7, 400–408
51. Bartus, R.T. et al. (2013) Safety/feasibility of targeting the
substantia nigra with AAV2-neurturin in Parkinson patients.
Neurology 80, 1698–1701
52. Bartus, R.T. et al. (2011) Bioactivity of AAV2-neurturin gene
therapy (CERE-120): differences between Parkinson’s disease
and nonhuman primate brains. Mov. Disord. 26, 27–36
53. Bartus, R.T. et al. (2015) Post-mortem assessment of the short
and long-term effects of the trophic factor neurturin in patients
with α-synucleinopathies. Neurobiol. Dis. 78, 162–171
54. Goetz, C.G. et al. (2008) Placebo response in Parkinson’s disease:
comparisons among 11 trials covering medical and surgical
interventions.Mov. Disord. 23, 690–699
55. Espay, A.J. et al. (2015) Placebo effect of medication cost in
Parkinson disease: a randomized double-blind study. Neurology
84, 794–802
56. Love, S. et al. (2005) Glial cell line–derived neurotrophic factor in-
duces neuronal sprouting in human brain. Nat. Med. 11, 703–704
57. Chu, Y. et al. (2020) Long-term post-mortem studies following
neurturin gene therapy in patients with advanced Parkinson’s
disease. Brain 143, 960–975
58. Bartus, R.T. and Johnson, E.M. (2017) Clinical tests of neuro-
trophic factors for human neurodegenerative diseases, part 2:
where do we stand and where must we go next? Neurobiol.
Dis. 97, 169–178
59. Piltonen, M. et al. (2009) Heparin-binding determinants of GDNF
reduce its tissue distribution but are beneficial for the protection
of nigral dopaminergic neurons. Exp. Neurol. 219, 499–506
60. Voutilainen, M.H. et al. (2009) Mesencephalic astrocyte-derived
neurotrophic factor is neurorestorative in rat model of Parkinson’s
disease. J. Neurosci. 29, 9651–9659
61. Hellman, M. et al. (2011) Mesencephalic astrocyte-derived
neurotrophic factor (MANF) has a unique mechanism to rescue
apoptotic neurons. J. Biol. Chem. 286, 2675–2680
62. Dietz, G.P.H. et al. (2006) Application of a blood–brain-barrier-
penetrating form of GDNF in a mouse model for Parkinson’s
disease. Brain Res. 1082, 61–66
63. Zhou, Q.-H. et al. (2010) Monoclonal antibody-glial-derived neu-
rotrophic factor fusion protein penetrates the blood-brain barrier
in the mouse. Drug Metab. Dispos. 38, 566–572
64. Zhou, Q. et al. (2011) Chronic dosing of mice with a transferrin
receptor monoclonal antibody-glial-derived neurotrophic factor
fusion protein. Drug Metab. Dispos. 39, 1149–1154
65. Fu, A. et al. (2010) Intravenous treatment of experimental
Parkinson’s disease in themousewith an IgG-GDNF fusion protein
that penetrates the blood–brain barrier.Brain Res. 1352, 208–213
66. Aly, A.E.E. et al. (2019) Intranasal delivery of pGDNF DNA nano-
particles provides neuroprotection in the rat 6-hydroxydopamine
model of Parkinson’s disease. Mol. Neurobiol. 56, 688–701
67. Pedersen, M.V. et al. (2004) Neuritogenic and survival-
promoting effects of the P2 peptide derived from a homophilic
binding site in the neural cell adhesion molecule. J. Neurosci.
Res. 75, 55–65
68. Mahato, A.K. et al. (2020) Glial cell line–derived neurotrophic
factor receptor rearranged during transfection agonist supports
dopamine neurons in vitro and enhances dopamine release
in vivo. Mov. Disord. 35, 245–255
69. Sidorova, Y.A. et al. (2017) A novel small molecule GDNF receptor
RET agonist, BT13, promotes neurite growth from sensory
neurons in vitro and attenuates experimental neuropathy in the
rat. Front. Pharmacol. 8, 1–18
70. Jmaeff, S. et al. (2020) Small-molecule agonists of the RET
receptor tyrosine kinase activate biased trophic signals that are
influenced by the presence of GFRα1 co-receptors. J. Biol.
Chem. 295, 6532–6542
71. Jmaeff, S. et al. (2020) Small-molecule ligands that bind the RET
receptor activate neuroprotective signals independent of but
modulated by co-receptor GFRα1. Mol. Pharmacol. Published
online May 3, 2020. https://doi.org/10.1124/mol.119.118950
72. Mahato, A.K. et al. (2019) GDNF receptor agonist supports
dopamine neurons in vitro and protects their function in
animal model of Parkinson’s disease. bioRxiv Published online
February 4, 2019. https://doi.org/10.1101/540021
73. Tysnes, O.-B. and Storstein, A. (2017) Epidemiology of
Parkinson’s disease. J. Neural Transm. 124, 901–905
74. Schapira, A.H.V. et al. (2017) Non-motor features of Parkinson
disease. Nat. Rev. Neurosci. 18, 435–450
75. Poewe, W. et al. (2017) Parkinson disease. Nat. Rev. Dis. Prim.
3, 17013
76. Wakabayashi, K. et al. (2013) The Lewy body in Parkinson’s
disease and related neurodegenerative disorders.Mol. Neurobiol.
47, 495–508
77. Hempstead, B.L. (2009) Commentary: Regulating proNGF action:
multiple targets for therapeutic intervention. Neurotox. Res. 16,
255–260
78. Sidorova, Y.A. et al. (2019)Neuroregeneration in Parkinson’s disease:
from proteins to small molecules. Curr. Neuropharmacol. 17,
268–287
79. Lindholm, P. et al. (2007) Novel neurotrophic factor CDNF pro-
tects and rescues midbrain dopamine neurons in vivo. Nature
448, 73–77Trends in Pharmacological Sciences, December 2020, Vol. 41, No. 12 921
Trends in Pharmacological Sciences80. Airavaara, M. et al. (2012) CDNF protects the nigrostriatal dopa-
mine system and promotes recovery after MPTP treatment in
mice. Cell Transplant. 21, 1213–1223
81. Parkash, V. et al. (2009) The structure of the conserved neurotrophic
factorsMANF and CDNF explains why they are bifunctional. Protein
Eng. Des. Sel. 22, 233–241
82. Bai, M. et al. (2018) Conserved roles of C. elegans and human
MANFs in sulfatidebindingand cytoprotection.Nat.Commun.9, 897
83. Rai, S.N. and Singh, P. (2020) Advancement in the modelling and
therapeutics of Parkinson’s disease. J. Chem. Neuroanat. 104,
101752
84. Airavaara, M. et al. (2020) Back and to the future: from
neurotoxin-induced to human Parkinson’s disease models.
Curr. Protoc. Neurosci. 91, e88
85. Pang, S.Y.-Y. et al. (2019) The interplay of aging, genetics
and environmental factors in the pathogenesis of Parkinson’s
disease. Transl. Neurodegener. 8, 23
86. Decressac, M. et al. (2012) Comparison of the behavioural
and histological characteristics of the 6-OHDA and α-synuclein
rat models of Parkinson’s disease. Exp. Neurol. 235,
306–315
87. Breger, L.S. and Fuzzati Armentero, M.T. (2019) Genetically
engineered animal models of Parkinson’s disease: from worm
to rodent. Eur. J. Neurosci. 49, 533–560
88. Wegrzynowicz, M. et al. (2019) Depopulation of dense α-synuclein
aggregates is associated with rescue of dopamine neuron dys-
function and death in a new Parkinson’s disease model. Acta
Neuropathol. 138, 575–595
89. Luk, K.C. et al. (2009) Exogenous -synuclein fibrils seed
the formation of Lewy body-like intracellular inclusions
in cultured cells. Proc. Natl. Acad. Sci. U. S. A. 106,
20051–20056
90. Abdelmotilib, H. et al. (2017) α-Synuclein fibril-induced inclu-
sion spread in rats and mice correlates with dopaminergic
neurodegeneration. Neurobiol. Dis. 105, 84–98
91. Galter, D. et al. (2010) MitoPark mice mirror the slow progression
of key symptoms and L-DOPA response in Parkinson’s disease.
Genes Brain Behav. 19, 173–181922 Trends in Pharmacological Sciences, December 2020, Vol. 41, No. 12
